Prevalence and characteristics of allodynia in headache sufferers: a population study
- PMID: 18427069
- PMCID: PMC2664547
- DOI: 10.1212/01.wnl.0000310645.31020.b1
Prevalence and characteristics of allodynia in headache sufferers: a population study
Abstract
Objective: The authors estimated the prevalence and severity of cutaneous allodynia (CA) in individuals with primary headaches from the general population.
Methods: We mailed questionnaires to a random sample of 24,000 headache sufferers previously identified from the population. The questionnaire included the validated Allodynia Symptom Checklist (ASC) as well as measures of headache features, disability, and comorbidities. We modeled allodynia as an outcome using headache diagnosis, frequency and severity of headaches, and disability as predictor variables in logistic regression. Covariates included demographic variables, comorbidities, use of preventive medication, and use of opioids.
Results: Complete surveys were returned by 16,573 individuals. The prevalence of CA of any severity (ASC score >or=3) varied with headache type. Prevalence was significantly higher in transformed migraine (TM, 68.3%) than in episodic migraine (63.2%, p < 0.01) and significantly elevated in both of these groups compared with probable migraine (42.6%), other chronic daily headaches (36.8%), and severe episodic tension-type headache (36.7%). The prevalence of severe CA (ASC score >or=9) was also highest in TM (28.5%) followed by migraine (20.4%), probable migraine (12.3%), other chronic daily headaches (6.2%), and severe episodic tension-type headache (5.1%). In the migraine and TM groups, prevalence of CA was higher in women and increased with disability score. Among migraineurs, CA increased with headache frequency and body mass index. In all groups, ASC scores were higher in individuals with major depression.
Conclusions: Cutaneous allodynia (CA) is more common and more severe in transformed migraine and migraine than in other primary headaches. Among migraineurs, CA is associated with female sex, headache frequency, increased body mass index, disability, and depression.
Figures
Similar articles
-
Predicting Inadequate Response to Acute Migraine Medication: Results From the American Migraine Prevalence and Prevention (AMPP) Study.Headache. 2016 Nov;56(10):1635-1648. doi: 10.1111/head.12941. Epub 2016 Oct 12. Headache. 2016. PMID: 27731896
-
Factors associated with triptan use in episodic migraine: results from the American Migraine Prevalence and Prevention Study.Headache. 2012 Feb;52(2):213-23. doi: 10.1111/j.1526-4610.2011.02032.x. Headache. 2012. PMID: 22413150
-
Allodynia in migraine: association with comorbid pain conditions.Headache. 2009 Oct;49(9):1333-44. doi: 10.1111/j.1526-4610.2009.01521.x. Headache. 2009. PMID: 19788473
-
Non-pharmacological educational and self-management interventions for people with chronic headache: the CHESS research programme including a RCT.Southampton (UK): National Institute for Health and Care Research; 2023 Jun. Southampton (UK): National Institute for Health and Care Research; 2023 Jun. PMID: 37463270 Free Books & Documents. Review.
-
The prevalence and impact of headache in Brazil.Headache. 2015 Feb;55 Suppl 1:32-8. doi: 10.1111/head.12511. Epub 2015 Feb 6. Headache. 2015. PMID: 25659407 Review.
Cited by
-
The effectiveness and predictors influencing the outcome of onabotulinumtoxinA treatment in chronic migraine: understanding from diverse patient profiles in a single session.Front Neurol. 2024 Jun 19;15:1417303. doi: 10.3389/fneur.2024.1417303. eCollection 2024. Front Neurol. 2024. PMID: 38962481 Free PMC article.
-
SIRT1-regulated ROS generation activates NMDAR2B phosphorylation to promote central sensitization and allodynia in a male chronic migraine rat model.Front Mol Neurosci. 2024 May 22;17:1387481. doi: 10.3389/fnmol.2024.1387481. eCollection 2024. Front Mol Neurosci. 2024. PMID: 38840778 Free PMC article.
-
Novel insight into atogepant mechanisms of action in migraine prevention.Brain. 2024 Aug 1;147(8):2884-2896. doi: 10.1093/brain/awae062. Brain. 2024. PMID: 38411458 Free PMC article.
-
Translation, cross-cultural adaptation and measurement proprieties of the German version of the Allodynia Symptom Checklist (ASC-12).J Headache Pain. 2023 Dec 1;24(1):160. doi: 10.1186/s10194-023-01697-9. J Headache Pain. 2023. PMID: 38041009 Free PMC article.
-
Depression and treatment with anti-calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies for migraine.Eur J Neurol. 2024 Feb;31(2):e16106. doi: 10.1111/ene.16106. Epub 2023 Oct 17. Eur J Neurol. 2024. PMID: 37847221 Free PMC article.
References
-
- Sivilotti L, Woolf CJ. The contribution of GABAA and glycine receptors to central sensitization: disinhibition and touch-evoked allodynia in the spinal cord. J Neurophysiol. 1994;72:169–179. - PubMed
-
- Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain. 2000;123:1703–1709. - PubMed
-
- Sessle BJ, Hu JW, Amano N, Zhong G. Convergence of cutaneous, tooth pulp, visceral, neck and muscle afferents onto nociceptive and non-nociceptive neurones in trigeminal subnucleus caudalis (medullary dorsal horn) and its implications for referred pain. Pain. 1986;27:219–235. - PubMed
-
- Wolff HG, Tunis MM, Goodell H. Studies on migraine. Arch Intern Med. 1953;92:478–484. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous